

Clinical Oversight Review Board (CORB) Criteria for Prescribing Imetelstat (Rytelo)

Notes:

- Quantity Limits: Yes
- * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

Non-Formulary **imetelstat (Rytelo)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria:

- Prescribed by oncologist or hematologist
- Patient has a diagnosis of low or intermediate risk MDS with transfusion-dependent anemia requiring 4 or more RBC units over 8 weeks
- Patient has failed an adequate trial[^] of erythropoietin stimulating agents or patient has an allergy or intolerance* to ESA.
-AND-
- Patient has failed an adequate trial of luspatercept (Reblozyl)

Criteria for *current Kaiser Permanente members already taking the medication who have not been reviewed previously:*

- Patient has a diagnosis of low or intermediate risk MDS with transfusion-dependent anemia requiring 4 or more RBC units over 8 weeks

Criteria for *new members entering Kaiser Permanente already taking the medication who have not been reviewed previously:*

- Patient has a diagnosis of low or intermediate risk MDS with transfusion-dependent anemia requiring 4 or more RBC units over 8 weeks